
About
IRBM is a drug discovery research organization in Pomezia, near Rome, Italy. It supports programs from target validation through preclinical candidate selection across small molecules, peptides, antibodies, and cell therapy, serving pharmaceutical companies, biotech firms, foundations, and other research partners. Its work covers chemistry, biology, DMPK, in vivo pharmacology, structural biology, and specialized disease-area assays.
Services
Integrated drug discovery projects
Runs coordinated programs from target validation through preclinical candidate selection on a single site with one team.
Small molecule discovery
Advances small molecule programs from screening hits to preclinical candidates.
Medicinal chemistry
Designs, makes, tests, and analyzes compounds through iterative DMTA cycles to optimize chemical series.
Synthetic chemistry
Develops synthetic routes, parallel synthesis, scale-up, and purification to produce target compounds and libraries.
Computational chemistry
Uses structure-based and ligand-based in silico methods to support target analysis, hit identification, hit-to-lead, and lead optimization.
Peptide discovery
Develops peptide programs from starting sequence to candidate, including macrocyclic, complex, and protein peptides.
Antibody discovery
Identifies, characterizes, and validates monoclonal antibodies.
Display technologies
Provides peptide phage display, antibody phage display, and mRNA display for discovery workflows.
11 more services
- Assay development
- High throughput screening
- High content screening
- Biophysical approaches
- Functional genomics
- Protein production
- NMR
- DMPK
- In vivo pharmacology
- Spatial biology
- Bioinformatics
- Lead time
- Results become a decision within days
- What to send
- Target hypothesis and the disease context behind it
- a validated target and an assay ready to run at scale
- Compound collections
- Confirmed hit
- Sequence
Capabilities
As they state on their website or in their listing.
- Processes
- Small molecule
- Antibody
- Peptide
- Cell therapy
- Recombinant protein
- In vivo
6 more
- Phage display
- ADME
- NMR
- HTS
- High-content imaging
- Bioanalysis
- Capacity
- Compound collection of more than 400,000 high quality molecules
- Single research hub in Rome, Italy
- Data supplied
- NMR · HPLC
Equipment
- 400 MHz spectrometer
- 500 MHz Bruker spectrometer
- 600 MHz Bruker spectrometer
- Biotage purification stations
- HPLC
- Mass spectroscopy instruments
- UPLC
Certifications
As the company states them, with the certificate or registry record where there is one.
GLPSelf-reported
AAALACSelf-reported
Company
- Type
- CRO
- Founded
- 2019
- Quality
- Code of Ethics · Policies and Certifications · Environmental, Health and Safety Policy · Energy Policy · Diversity and Inclusion Policy · Gender Equality Policy
Locations
- Based in
- Pomezia, Italy
- Sites
- Pomezia (Rome), Italy · Rome, Italy
- Serves
- Italy, Europe, worldwide
Contacts
- General enquiry
- info@irbm.com on their site
Public records
- Wikidata
- Q24933575 source